These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 32108529

  • 1. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, Hapke E.
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [Abstract] [Full Text] [Related]

  • 2. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T, Amada N, Jungaberle H, Schecke H, Klein M.
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [Abstract] [Full Text] [Related]

  • 3. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS.
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [Abstract] [Full Text] [Related]

  • 4. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E.
    Harm Reduct J; 2019 Jul 10; 16(1):43. PubMed ID: 31288862
    [Abstract] [Full Text] [Related]

  • 5. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
    Rootman JM, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Polito V, Bourzat F, Walsh Z.
    Sci Rep; 2021 Nov 18; 11(1):22479. PubMed ID: 34795334
    [Abstract] [Full Text] [Related]

  • 6. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R, Anderson T, Maier LJ, Barratt MJ, Ferris JA, Winstock AR.
    J Psychopharmacol; 2022 Jan 18; 36(1):85-96. PubMed ID: 33591231
    [Abstract] [Full Text] [Related]

  • 7. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M.
    Psychopharmacology (Berl); 2020 May 18; 237(5):1521-1532. PubMed ID: 32043165
    [Abstract] [Full Text] [Related]

  • 8. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D.
    Elife; 2021 Mar 02; 10():. PubMed ID: 33648632
    [Abstract] [Full Text] [Related]

  • 9. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC.
    Int J Neuropsychopharmacol; 2019 Jul 01; 22(7):426-434. PubMed ID: 31152167
    [Abstract] [Full Text] [Related]

  • 10. Psychedelic Microdosing: A Subreddit Analysis.
    Lea T, Amada N, Jungaberle H.
    J Psychoactive Drugs; 2020 Jul 01; 52(2):101-112. PubMed ID: 31648596
    [Abstract] [Full Text] [Related]

  • 11. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
    Polito V, Liknaitzky P.
    J Psychopharmacol; 2024 Aug 01; 38(8):701-711. PubMed ID: 38877715
    [Abstract] [Full Text] [Related]

  • 12. Microdosing with classical psychedelics: Research trajectories and practical considerations.
    Wong A, Raz A.
    Transcult Psychiatry; 2022 Oct 01; 59(5):675-690. PubMed ID: 36317302
    [Abstract] [Full Text] [Related]

  • 13. Psychedelic Microdosing: Prevalence and Subjective Effects.
    Cameron LP, Nazarian A, Olson DE.
    J Psychoactive Drugs; 2020 Oct 01; 52(2):113-122. PubMed ID: 31973684
    [Abstract] [Full Text] [Related]

  • 14. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM, Nock MK.
    J Psychopharmacol; 2022 Jan 01; 36(1):46-56. PubMed ID: 34983249
    [Abstract] [Full Text] [Related]

  • 15. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.
    Rouaud A, Calder AE, Hasler G.
    J Psychopharmacol; 2024 Mar 01; 38(3):217-224. PubMed ID: 38214279
    [Abstract] [Full Text] [Related]

  • 16. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
    Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D.
    J Psychopharmacol; 2019 Sep 01; 33(9):1039-1057. PubMed ID: 31303095
    [Abstract] [Full Text] [Related]

  • 17. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
    Marschall J, Fejer G, Lempe P, Prochazkova L, Kuchar M, Hajkova K, van Elk M.
    J Psychopharmacol; 2022 Jan 01; 36(1):97-113. PubMed ID: 34915762
    [Abstract] [Full Text] [Related]

  • 18. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G.
    J Neurosci; 2021 Feb 03; 41(5):891-900. PubMed ID: 33257322
    [Abstract] [Full Text] [Related]

  • 19. Psychedelic use and intimate partner violence: The role of emotion regulation.
    Thiessen MS, Walsh Z, Bird BM, Lafrance A.
    J Psychopharmacol; 2018 Jul 03; 32(7):749-755. PubMed ID: 29807492
    [Abstract] [Full Text] [Related]

  • 20. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW.
    J Psychopharmacol; 2019 Sep 03; 33(9):1088-1101. PubMed ID: 31084460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.